^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tumor Mutational Burden in Blood May Predict Immunotherapy Response in Head, Neck Cancer
Published date:
06/04/2020
Excerpt:
At the 18-month mark, overall survival rates were significantly higher among TMB-high patients who were treated with durvalumab and durvalumab-tremelimumab than those treated with chemotherapy.
Test:
Source:
Title:
Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.
Published date:
05/13/2020
Excerpt:
OS and PFS HRs were significantly improved for D or D+T vs CT in pts with high bTMB (≥16 mut/Mb) vs low (<16 mut/Mb; Table). The benefit of D or D+T vs CT in pts with high bTMB generally improved with increasing cutoff….18-month OS rates were higher for D+T (22%; 95% CI 7%–42%) and D (33%; 95% CI 17%–51%) vs CT (0%; 95% CI 0%–0%) in pts with high bTMB.
DOI:
10.1200/JCO.2020.38.15_suppl.6511
Trial ID:
Source:
Title:
Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.
Published date:
05/13/2020
Excerpt:
In CONDOR, pts (D and D+T arms) with high TMB vs low had significantly longer OS (N = 76; 16.3 vs 5.3 m; HR = 0.53; 95% CI = 0.31-0.92).
DOI:
10.1200/JCO.2020.38.15_suppl.6548
Trial ID:
